Skip to main content
Clinical Trials/JPRN-jRCT1031220298
JPRN-jRCT1031220298
Recruiting
Phase 4

A double-blinded, randomised, clinical trial about the effect of rebamipide ophthalmic suspension in dry eye with the Sjogren syndrome patients. - Mucosta trial

Shimizu Daisuke0 sites40 target enrollmentAugust 27, 2022

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Patients with dry eye complicated by Sjogren's syndrome
Sponsor
Shimizu Daisuke
Enrollment
40
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 27, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Shimizu Daisuke

Eligibility Criteria

Inclusion Criteria

  • Patients who meet all of the following criteria will be considered
  • (1\) Written consent has been obtained from the patient or a surrogate
  • (2\) Men and women who are at least 18 years of age at the time of consent acquisition.
  • (3\) Patient must have a diagnosis of Sjogren's syndrome based on the revised diagnostic criteria of the Ministry of Health in 1999\.
  • (4\) Patient has a diagnosis of dry eye based on the revised dry eye practice guideline criteria by the 2019 Dry Eye Study Group Practice Guideline Development Committee.

Exclusion Criteria

  • Patients who meet all of the following criteria will be considered.
  • (1\) Patients with active inflammatory ocular or eyelid disease.
  • (2\) Patients with eyelid closure defects.
  • (3\) Patients with a history of graft\-versus\-host disease.
  • (4\) Other persons deemed by the principal investigator or subinvestigator to be inappropriate for the safe conduct of this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials